Phase 1 trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study).
Sina VatandoustTim BrightAmitesh Chandra RoyMuhammad Nazim AbbasDavid Ian WatsonSusan GanJeff BullMichael SorichAlex Scott-HoyLee-Jen LuuChristos Stelios KarapetisPublished in: Asia-Pacific journal of clinical oncology (2021)
IP paclitaxel is safe in combination with cisplatin and capecitabine and the recommended phase-2 dose is 30 mg/m2 .